Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$8.19
▼ $0.14 (-1.7%)
Market data updated: 09/25 05:00 AM
News analyzed: 09/25/2026
Market Cap
$140.10M
Day Range
$8.16 - $8.49
52-Week Range
$8.16 - $16.77
Beta
—
Next Earnings
—
Support
$8.16
Resistance
$14.68
RNA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-44.5% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 0/12 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
No notable strengths identified.
Computed directly from the same signals behind the score above — not AI-generated.
Biggest negative driver
Daily volatility (ATR)
ATR: 8.1% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 0 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
RNA exhibits a strong overall investor score of 77, driven primarily by robust technical performance and a neutral yet promising news sentiment. The technical category scores exceptionally high at 91, reflecting a clear bullish bias: the stock price remains above both its 50-day and 200-day moving averages, while the MACD histogram and RSI (63.7) indicate healthy upward momentum. However, the news category lags at 56, with neutral coverage dominating—highlighting cautious optimism around Atrium’s clinical pipeline and partnerships, such as the $15M milestone with Bristol-Myers Squibb, but lacking definitive positive catalysts. The risk score of 50 is minimal, with ATR (3.7%) suggesting moderate volatility, though this is typical for biotech stocks. The absence of concerns in the provided data further underscores the stock’s stability in this snapshot.
The stock price is firmly above both its 50-day and 200-day moving averages, with a positive MACD histogram and RSI of 63.7 indicating strong upward momentum. The %K at 75.0 reflects neutral short-term momentum strength.
This technical alignment suggests a sustained bullish trend with minimal near-term downside pressure, reinforcing investor confidence in the stock’s trajectory.
All news items are neutral, focusing on pipeline developments (e.g., Atrium’s milestones with Bristol-Myers Squibb) and investor conferences without clear positive or negative catalysts.
Neutral news sentiment implies limited near-term volatility but also highlights a lack of definitive catalysts to drive significant price movement.
The ATR (3.7% of price) indicates moderate volatility, which is typical for biotech stocks like RNA and reflects inherent uncertainty in clinical-stage developments.
While volatility is expected, it underscores the need for investors to monitor clinical progress and partnership milestones for potential upside or downside.
StockIQ conclusion
RNA demonstrates a balanced profile with strong technical fundamentals supporting its upward trajectory, though its neutral news sentiment and inherent biotech risks temper expectations. The absence of concerns and moderate volatility suggest stability, but the lack of definitive positive catalysts means the stock’s performance remains contingent on clinical and partnership developments. Investors should monitor pipeline milestones and regulatory progress for potential score changes.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
26
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
15d ago · $11.35
Evidence: Panic-selling score jumped from 4 to 47 day-over-day
What happened after
21d ago · $14.60
Evidence: +3.7pp vs. sector average today
What happened after
21d ago · $14.60
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
21d ago · $14.60
Evidence: 10 bullish / 2 bearish technical signals agreeing
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of September 2, 2026
Then
71
$13.77
Now
26
$8.19
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
9
Risk
42
Sentiment
62
Fundamental
No data available
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Atrium Therapeutics (NASDAQ: RNA) has centered on its advancing RNA therapeutics pipeline for cardiology, highlighting key milestones like FDA clearance for its first Phase 1/2 trial (Corventis) targeting disease-modifying treatments. The company also received a $15 million milestone payment from Bristol-Myers Squibb for delivering a lead RNA compound, reinforcing its collaboration potential. Analysts reiterated a "Buy" rating with an elevated price target, while investor conferences were announced to discuss its progress. Financial results and cash sustainability remain focal points amid growing clinical momentum.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Atrium Therapeutics, Inc.. News trend score: 62. Reason: 4 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
47
🎯 Conviction (vs. Emotion)
50
Psychology
93
Fundamentals
—
Technical
9
Valuation
—
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-38%
Market Narrative
37
Fundamental Reality
50
Narrative Gap
-13
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a tug-of-war between panic selling (high volatility, elevated volume) and anchoring (proximity to support), with herding dominating due to RNA’s outperformance relative to peers. The narrative gap (-13) hints at a disconnect where sentiment (37) lags reality (50), possibly amplifying reactive trading. Key open question: Will traders pivot from panic to defensive anchoring, or does the gap widen further? The dominant state may shift if volatility stabilizes or peer performance diverges.
Updated: 09/09/2026, 02:58 PM
What could change this?
👥 What the crowd believes
"$15 million milestone payment from Bristol-Myers Squibb after delivering a lead RNA compound"
"launch of Corventis, its first Phase 1/2 trial and the first study anywhere testing a disease-modifying"
"HC Wainwright & Co. reiterates Atrium Therapeutics (NASDAQ:RNA) with a Buy and maintains $25 price target"
📈 12D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 98/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between momentum-driven and fundamental investors. Top-scoring methodologies like Samuel Armstrong Nelson’s cycle analysis and Charles Mackay’s crowd psychology both flag it as undervalued or free from speculative frenzy, suggesting a favorable technical or behavioral setup. Meanwhile, disciplined traders like Jack Schwager and Howard Marks (Market Cycle) see it as a structured opportunity with balanced risk-reward, though Marks’ broader valuation approach pulls back slightly. In contrast, fundamentalists like Benjamin Graham, Philip Fisher, and Peter Lynch are stymied by insufficient data, while contrarian voices like Jesse Livermore and Morgan Housel outright dismiss it—Livermore due to trend resistance and Housel because of volatility. The split underscores whether this stock’s appeal lies in its technical or cyclical patterns (high scores) or whether its murky fundamentals and risk profile make it a non-starter for patient, data-dependent investors.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 98
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 92
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 91
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 90
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 51
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 50
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 42
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 27
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 26
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 144 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 11 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 4 positive, 14 neutral, 2 negative out of the last 20 articles.
Yahoo · 21.9.2026
Benzinga · 8.9.2026
Yahoo · 6.9.2026
Insider Monkey · 6.9.2026
Yahoo · 2.9.2026
PR Newswire · 2.9.2026
Yahoo · 28.8.2026
Insider Monkey · 28.8.2026
PR Newswire · 20.8.2026
Benzinga · 14.8.2026
PR Newswire · 13.8.2026
Benzinga · 13.8.2026
MT Newswires · 13.8.2026
PR Newswire · 13.8.2026
Benzinga · 13.8.2026
The Fly · 6.8.2026
Benzinga · 6.8.2026
Benzinga · 6.8.2026
PR Newswire · 20.7.2026
MT Newswires · 14.7.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Atrium Therapeutics, Inc. (RNA) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for RNA specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
RNA's technical score is 9/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: ATR: 8.1% of price; Price is below the 50-day average; MACD histogram is negative — falling momentum.
StockIQ has no recorded dividend payment history for RNA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Hughes Steven George | Tax Withholding in Shares | 18.9.2026 | 51,638 | -21,459 | $8.95 |
| Flanagan W. Michael | Tax Withholding in Shares | 18.9.2026 | 31,974 | -22,812 | $8.95 |
| Winslow Brendan R. | Tax Withholding in Shares | 18.9.2026 | 36,859 | -6,742 | $8.95 |
| Boyce Sarah | Tax Withholding in Shares | 18.9.2026 | 138,668 | -126,418 | $8.95 |
| Kenney Stephanie | Tax Withholding in Shares | 18.9.2026 | 33,085 | -2,375 | $8.95 |
| Hoyos Rocio Martin | Tax Withholding in Shares | 18.9.2026 | 38,340 | -8,320 | $8.95 |
| Younis Husam | Tax Withholding in Shares | 18.9.2026 | 41,441 | -11,216 | $8.95 |
| Gallagher Kathleen P. | Tax Withholding in Shares | 18.9.2026 | 119,729 | -11,632 | $8.95 |
| Hughes Steven George | Grant/Award from Employer | 20.4.2026 | 30,000 | +30,000 | — |
| Hoyos Rocio Martin | Grant/Award from Employer | 20.4.2026 | 60,000 | +60,000 | — |
| Kenney Stephanie | Grant/Award from Employer | 20.4.2026 | 60,000 | +60,000 | — |
| Hoyos Rocio Martin | Grant/Award from Employer | 20.4.2026 | 30,000 | +30,000 | — |
| Younis Husam | Grant/Award from Employer | 20.4.2026 | 60,000 | +60,000 | — |
| Kenney Stephanie | Grant/Award from Employer | 20.4.2026 | 30,000 | +30,000 | — |
| Hughes Steven George | Grant/Award from Employer | 20.4.2026 | 60,000 | +60,000 | — |
| Gallagher Kathleen P. | Grant/Award from Employer | 20.4.2026 | 205,000 | +205,000 | — |
| Winslow Brendan R. | Grant/Award from Employer | 20.4.2026 | 60,000 | +60,000 | — |
| Younis Husam | Grant/Award from Employer | 20.4.2026 | 30,000 | +30,000 | — |
| Winslow Brendan R. | Grant/Award from Employer | 20.4.2026 | 30,000 | +30,000 | — |
| Gallagher Kathleen P. | Grant/Award from Employer | 20.4.2026 | 102,500 | +102,500 | — |
| Hughes Steven George | Grant/Award from Employer | 20.4.2026 | 73,097 | +30,000 | — |
| Hughes Steven George | Grant/Award from Employer | 20.4.2026 | 60,000 | +60,000 | — |
| Gallagher Kathleen P. | Grant/Award from Employer | 20.4.2026 | 131,361 | +102,500 | — |
| Gallagher Kathleen P. | Grant/Award from Employer | 20.4.2026 | 205,000 | +205,000 | — |
| Younis Husam | Grant/Award from Employer | 20.4.2026 | 52,657 | +30,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,397,791 shares short as of 2026-09-15 · vs. 3,351,526 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
22.0% of trading volume this week was short selling, vs. 35.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology